Kuldeep Gupta PhD
University of Arizona College of Medicine, Kennedy Krieger Institute, Birla Institute of Technology and Science, Annamalai University, Johns Hopkins Medicine, Chhatrapati Shahu Ji Maharaj University
About
I am a passionate and innovative researcher with over fifteen years of experience in immunology, immuno-oncology, microbiology, and infectious diseases. My mission is to bring meaningful impact to patients' lives by discovering novel mechanisms and targets for therapeutic interventions.
Currently, I am working as a Senior Research Scientist in College of Medicine, University of Arizona, Phoenix. Previously, I worked as a postdoctoral research fellow in Radiology Department, Johns Hopkins University Medicines, USA and before that University of North Dakota, Grand Forks. My research work are multidimensional which includes, evaluating the immune-tolerance levels, pharmacokinetics, and tumor regression capabilities of novel agents through non-invasive mode of imaging methods (PET/CT), biodistribution, flow cytometry, immunohistochemistry and other molecular biology techniques.
My research work has involved various immunological, cellular, molecular and biochemical determinants. I took advantage of opportunities to conduct research applying immune-modulating mechanism assessment for sepsis and haematopoesis, and want to utilize my background in further research studies of infection and inflammation.
Employment
-
University of Arizona College of Medicine Research Scientist - III2024 - Present
-
Kennedy Krieger Institute Senior Research Associate2023 - 2024
-
Johns Hopkins Medicine Postdoctoral Research Fellow2020 - 2023
-
University of North Dakota Postdoctoral Research Fellow2016 - 2020
Education
-
Birla Institute of Technology and Science PhD2010 - 2016
-
Annamalai University M.Phil.2006 - 2008
-
Chhatrapati Shahu Ji Maharaj University Advanced PG Diploma in Bioinformatics2004 - 2005
-
Chhatrapati Shahu Ji Maharaj University M.Sc.2002 - 2004
Projects & Funding
Projects & funding information is unavailable.
Publications (53)
- Nectin-4 PET for predicting enfortumab vedotin dose-response in urothelial carcinoma. Save
- Data from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Save
- Supplementary Figure S1 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Save
- Supplementary Figure S2 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Save
- Supplementary Figure S3 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Save
- Supplementary Figure S4 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Save
- Supplementary Figure S5 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Save
- Supplementary Figure S6 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Save
- Supplementary Figure S7 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics Save
- EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment Save